Literature DB >> 8097663

The triggering of spreading depression in the chicken retina: a pharmacological study.

M J Sheardown1.   

Abstract

Spreading depression (S.D.) can be reproducibly evoked in the retinas of 3- to 6-day-old chickens by K+ ions, N-methyl-D-aspartate (NMDA), kainate (KA), and quisqualate (QA). Specific NMDA antagonists inhibit S.D. evoked by all the above agents. The very selective non-NMDA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX) blocks QA- and KA-evoked S.D. but not NMDA- or K(+)-evoked S.D. These findings indicate that NMDA receptor activation is the vital event in the triggering of S.D. in this tissue, and that QA and KA trigger S.D. indirectly via excitation of NMDA receptors. Tetrodotoxin, cadmium chloride, conotoxin, baclofen and adenosine agonists are all ineffective in blocking K(+)-, NMDA-, QA- or KA-evoked S.D. L-trans-Pyrrolidine-2,4-dicarboxylic acid, a glutamate uptake blocker, does inhibit QA-evoked S.D. It is therefore argued that a presynaptic release of vesicular, glutamate 'neurotransmitter stores' is not the mechanism of action of QA and KA. A mechanism involving a reversal of the glutamate uptake carrier is suggested.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097663     DOI: 10.1016/0006-8993(93)91506-n

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

Review 1.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Synaptic connections of starburst amacrine cells and localization of acetylcholine receptors in primate retinas.

Authors:  Elizabeth S Yamada; Nina Dmitrieva; Kent T Keyser; Jon M Lindstrom; Louis B Hersh; David W Marshak
Journal:  J Comp Neurol       Date:  2003-06-16       Impact factor: 3.215

3.  The use of time-lapse optical coherence tomography to image the effects of microapplied toxins on the retina.

Authors:  Joseph A Majdi; Haohua Qian; Yichao Li; Robert J Langsner; Katherine I Shea; Anant Agrawal; Daniel X Hammer; Joseph P Hanig; Ethan D Cohen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-18       Impact factor: 4.799

4.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

5.  Effects of NMDA receptor antagonists with different subtype selectivities on retinal spreading depression.

Authors:  Minyan Wang; Paul L Chazot; Sura Ali; Stevens F Duckett; Tihomir P Obrenovitch
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 6.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

7.  ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.

Authors:  L Turski; A Huth; M Sheardown; F McDonald; R Neuhaus; H H Schneider; U Dirnagl; F Wiegand; P Jacobsen; E Ottow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex.

Authors:  T P Obrenovitch; E Zilkha
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  Cortical spreading depression-new insights and persistent questions.

Authors:  A Charles; Kc Brennan
Journal:  Cephalalgia       Date:  2009-10       Impact factor: 6.292

10.  Comparison of the AMPA antagonist action of new 2,3-benzodiazepines in vitro and their neuroprotective effects in vivo.

Authors:  Gábor Kapus; Szabolcs Kertész; Gábor Gigler; Annamária Simó; Miklos Vegh; József Barkóczy; László G Hársing; Géza Szabó; György Lévay
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.